Japan’s recent Upper House election delivered a stinging defeat for the ruling Liberal Democratic Party (LDP) and junior coalition partner…
HOME > September 9, 2021
Daily News
September 9, 2021
- SymBio Starts Nonclinical Study of Brincidofovir IV for Brain Tumors
September 9, 2021
- Kyowa Kirin Bags Japan Rights to AM-Pharma’s SA-AKI Drug
September 9, 2021
- Systemic Symptoms Unlikely to Occur from Contaminated Moderna Jabs: Japan Vaccinology Society
September 9, 2021
- Opdivo/Yervoy Gets First-Line OK for Malignant Pleural Mesothelioma in Taiwan
September 9, 2021
- Mitsubishi Tanabe Launches Global PII Study for Spinal Cord Injury Drug
September 9, 2021
- Rohto, Osaka Univ., and AI Firm to Develop New Solution for Predicting Systemic Diseases from Fundus Data
September 9, 2021
- Shionogi Forms Capital Alliance with Robotic Startup to Develop New Solutions
September 9, 2021
- Drug Makers’ Detailing Activities Collectively Down in July: Intage
September 9, 2021
- Follow-On AGs Gaining Ground with 10 Launches in 2 Years, More Expected amid Generic Quality Concerns
September 9, 2021
A recent conversation with a US biopharma senior director highlighted a critical talent gap: a strong demand for individuals with strategic management, critical thinking, and advanced business acumen-skills beyond traditional operational excellence. After the conversation, I rushed home and picked…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…